Humira U.S. sales expectations were softer than the previous outlook due to the impact of a retail specialty pharmacy destocking in the first quarter and a conservative stance on co-pay costs associated with co-pay accumulator programs. Internationally, Humira sales are expected to approach $6.4 billion, up from $6.2 billion previously, which includes the expected impact of biosimilar entrants in Europe in the fourth quarter. First-quarter net revenues from Imbruvica were $762 million, up 38.5% year over year.